

Recent progress in surface-enhanced Raman spectroscopy-based biosensors for the detection of extracellular vesicles

Hong Zheng^{#a}, Qin Ding^{#b}, Chen Li^a, Wei Chen^a, Xiaoqiang Chen^a, Qin Lin^a, Desheng Wang^{*a},
Youliang Weng^{*b} and Duo Lin^{*b}

^a Department of Otolaryngology Head and Neck Surgery, Fujian Medical University Union Hospital, Fuzhou, China

^b Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou, Fujian, China

^c Key Laboratory of OptoElectronic Science and Technology for Medicine, Ministry of Education, Fujian Provincial Key Laboratory for Photonics Technology, Fujian Normal University, Fuzhou, China

Table S1. peak assignments of surface-enhanced Raman spectroscopy of cell-derived EVs

Peak (cm ⁻¹)	Origin	EVs source	Substrates
406	cholesterol	RBC	EVs with Au@AgNPs ¹
486,487	Polysaccharide	B16F10(melanoma cell), RBC normal cell(alveolar cell)	EVs coated with AuNP ² GNP substrates ³
505,521	S-S stretching(proteins)	H1975(lung cancer cell) B16F10(melanoma cell), RBC	Ag NCs on Au NR array substrate ⁴ EVs with Au@AgNPs ¹ EVs coated with AuNP ²
537	Cholesterol ester, Adenosine, S-S difulfide dridge in cysteine	normal cell(alveolar cell) Lung cancer cell HPAEpiC(normal cell)	GNP substrates ^{3, 5}
546	cholesterol	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹ EVs coated with AuNP ²
570	Carbohydrate present in cell membrane	H1299, H522(lung cancer cells)	GNP substrates ³
602	CCO	H1299, H522(lung cancer cells)	GNP substrates ³
615,625,630	C - C twisting(proteins)	SKOV-3(ovarian cancer cell) NL-20, BEAS-20, L929(lung normal cells) PC-9(lung cancer cell)	3D plasmonic nanobowl platform ⁶ Ag NCs on Au NR array substrate ⁴
643,645,647,648	C - C twisting(Tyr)	SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC Lung cancer cell, HPAEpiC(normal cell)	biosilica/AgNP composite substrates ⁷ 3D plasmonic nanobowl platform ⁶ EVs with Au@AgNPs ¹ GNP substrates ⁵
650	C-S stretching	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
667	N - type sugar pucker	PANC1(Pancreatic cancer cell)	EVs with nanostars ⁸
668	T, G (DNA/RNA)	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹
700	Cholesterol, cholesterol ester, C-S stretching mode	normal cell(alveolar cell)	GNP substrates ³

707	Aminoacid, lipid band due to cholesterol	SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC MDA-MB-231(breast cancer cell)	3D plasmonic nanobowl platform ⁶ EVs with Au@AgNPs ¹ GO-GNS mixed-dimensional substrate ⁹
714,725,727, 729,732	Met, Adenine, Ser	normal cell SKOV-3(ovarian cancer cell) PANC1(Pancreatic cancer cell) H1299, H522(lung cancer cells)	GNP substrates ³ 3D plasmonic nanobowl platform ⁶ EVs with nanostars ⁸
735	C–S stretching	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
754,760	Trp	PANC1(Pancreatic cancer cell) SKOV-3(ovarian cancer cell)	EVs with nanostars ⁸ 3D plasmonic nanobowl platform ⁶
781,786,788	Cytosine ring breathing mode, DNA backbone phosphodiester symmetric stretch	H1299, H522(lung cancer cells) SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC PANC1(Pancreatic cancer cell) normal cell	GNP substrates ³ 3D plasmonic nanobowl platform ⁶ EVs with Au@AgNPs ¹ EVs with nanostars ⁸
789-795	vibrations in nucleic acid	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
805	Si–O stretching, predominantly silicon motion	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
813,819	Ribose	Lung cancer cell HPAEpiC(normal cell)	GNP substrates ⁵
830,831	Tyr	SKOV-3(ovarian cancer cell) Lung cancer cell	3D plasmonic nanobowl platform ⁶ GNP substrates ⁵
838	Amine group	H1299, H522(lung cancer cells)	GNP substrates ³
843	Glucose	H1299, H522(lung cancer cells)	GNP substrates ³

847.4	Monosaccharides(α -glucose, (C-O-C) skeletal mode	H1975(lung cancer cell)	Au nanopyramid hybrid substrate ¹⁰
850	lipids,t(C – C) vibration	CCD841-CoN(normal cell) HCT116(Colon cancer cell)	Super-hydrophobic substrate ¹¹
852,854.4	Ring breathing Tyr (proteins)	SKOV-3(ovarian cancer cell) HCC827(lung cancer cell)	3D plasmonic nanobowl platform ⁶ Au nanopyramid hybrid substrate ¹⁰
869	Pro	H1299, H522(lung cancer cells)	GNP substrates ³
871	Tyr	Lung cancer cell HPAEpiC(normal cell)	GNP substrates ⁵
879	Trp	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
883	ρ (CH ₂)(protein)	B16F10(melanoma cell)	EVs coated with AuNP ²
903	carbohydrate-related SERS vibrations	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
911	Glucose, Ring breathing mode	H1299, H522(lung cancer cells)	GNP substrates ³
920	Protein	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
925,927,931	Pro, Val	Lung cancer cell HPAEpiC(normal cell) SKOV-3(ovarian cancer cell)	GNP substrates ⁵ biosilica/AgNP composite substrates ⁷
937	Protein	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
942,944,948,960	C – C – N stretching (e.g. α -helix backbone in protein)	Lung cancer cell HPAEpiC(normal cell) PANC1(Pancreatic cancer cell) SKOV-3(ovarian cancer cell)	GNP substrates ⁵ EVs with nanostars ⁸ biosilica/AgNP composite substrates ⁷
970	lipid band due to Phosphate monoester groups	MDA-MB-231(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1000,1003	Phe	SKOV-3(ovarian cancer cell) H1975(lung cancer cell)	3D plasmonic nanobowl platform ⁶ Ag NCs on Au NR array

		cell)	substrate ⁴
		PANC1(Pancreatic cancer cell)	EVs with nanostars ⁸ EVs with Au@AgNPs ¹
1010,1050,1090	Si-O stretching; oxygen vibrating between silicon in the Si-O-Si bond	RBC SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1014	tryptophan band due to the ring breathing	SK-BR3(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1015	C-C stretching vibration possibly coupled to C-N stretching vibration	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1016,1017	Phe	Lung cancer cell HPAEpiC(normal cell)	GNP substrates ⁵
1032,1033,1034.3,1038	CH ₂ CH ₃ bending,t(C - C) vibration, Pro	B16F10(melanoma cell), RBC CCD841-CoN, HPAEpiC(normal cells) HCC827(lung cancer cell) HCT116(Colon cancer cell)	EVs coated with AuNP ² GNP substrates ⁵ Au nanopyramid hybrid substrate ¹⁰ Super-hydrophobic substrate ¹¹
1050	Lipid	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1056	lipid band is due to C • • O stretch	MDA-MB-231(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1058,1059	DNA bases	Lung cancer cell, HPAEpiC(normal cells)	GNP substrates ⁵
1072	Mannose, C-N stretching mode	H1299, H522(lung cancer cells)	GNP substrates ³
1095,1101	PO ₂ - stretching, C-C stretching, C-O stretching, glycosidic link in	SKOV-3(ovarian cancer cell) SK-BR3(breast cancer cell)	biosilica/AgNP composite substrates ⁷ GO-GNS mixed-dimensional substrate ⁹

DNA/RNA			
1110,1113.6,1115, 1120,1120.3	The strong C-O band of ribose (serves as a marker band for RNA in solutions), Nucleic acid	SKOV-3(ovarian cancer cell) H1975, HCC827(lung cancer cell) B16F10(melanoma cell), RBC	biosilica/AgNP composite substrates ⁷ Au nanopyramid hybrid substrate ¹⁰ EVs coated with AuNP ² 3D plasmonic nanobowl platform ⁶
1124,1134	t(C - C) inphase aliphatic C - C stretch of lipids	CCD841-CoN(normal cell) HCT116(Colon cancer cell) B16F10(melanoma cell), RBC	EVs coated with AuNP ² Super-hydrophobic substrate ¹¹ EVs coated with AuNP ²
1145	CH ₂ , CH ₃ deformations in proteins and lipids	H1299, H522(lung cancer cells)	GNP substrates ³
1150	Deoxyribose phosphate backbone (C-C stretching mode), Adenosine, Thymine, Glycogen	normal cell(alveolar cell)	GNP substrates ³
1160-1170	carbohydrate-related SERS vibrations	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1172	δ (C H) (e.g., protein)	B16F10(melanoma cell), RBC	EVs coated with AuNP ²
1175	Tyr, Phe	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1175	nucleic acid vibrations in DNA/RNA, phenylalanine, or tyrosine vibrations in proteins	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1179	ν (C-C) and ν (C-O) (phospholipids)	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹ EVs coated with AuNP ²

1198,1207, 1211,1213.5	Tyr, Phe ν (C-C6H6) mode, Stretching of C-N	SK-BR3(breast cancer cell) SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC HCC827, H1975(lung cancer cells) normal cell(alveolar cell)	GO-GNS mixed- dimensional substrate ⁹ 3D plasmonic nanobowl platform ⁶ EVs with Au@AgNP ¹ Au nanopyramid hybrid substrate ¹⁰ GNP substrates ³
1217,1222, 1238.4	Amide III	HPAEpiC(normal cell) HCC827(lung cancer cell)	GNP substrates ⁵ Au nanopyramid hybrid substrate ¹⁰
1235	ribonucleic acid from Uraci	CCD841-CoN(normal cell) HCT116(Colon cancer cell)	Super-hydrophobic substrate ¹¹
1240	C-N stretching + N -H deformation, amide III in proteins	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1243,1253.5,1254,1256, 1260,1271	amide III (proteins)/ asymmetric phosphate stretching (nucleic acids), CH2 in-plane deformation (lipids), Triglycerides (fatty acids)	B16F10(melanoma cell), RBC PC-9, H1975, HCC827(lung cancer cells) NL-20, BEAS-20, L929(lung normal cells) SKOV-3(ovarian cancer cell) MDA-MB-231(breast cancer cell)	EVs with Au@AgNPs ¹ EVs coated with AuNP ² Au nanopyramid hybrid substrate ¹⁰ Ag NCs on Au NR array substrate ⁴ 3D plasmonic nanobowl platform ⁶ GO-GNS mixed- dimensional substrate ⁹
1278	ribonucleic acid from Cytosine	CCD841-CoN(normal cell), HCT116(Colon cancer cell)	Super-hydrophobic substrate ¹¹
1287,1290,1293,1295	CH2,CH3 deformation/C-N stretching + N-H deformation; amide III in proteins	SKOV-3(ovarian cancer cell) B16F10(melanoma cell) PANC1(Pancreatic cancer cell)	biosilica/AgNP composite substrates ⁷ EVs coated with AuNP ² EVs with nanostars ⁸

1303,1307, 1309.3	C–N asymmetric stretching (protein)/CH ₃ CH ₂ twisting (lipid)	SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC H1975(lung cancer cell)	3D plasmonic nanobowl platform ⁶ EVs with Au@AgNPs ¹ EVs coated with AuNP ² Au nanopyramid hybrid substrate ¹⁰
1310-1340	carbohydrate-related SERS vibrations	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1310,1313	Trp, C α -H	Lung cancer cell, HPAEpiC(normal cells)	GNP substrates ⁵
1326	ω CH ₃ CH ₂ twisting (nucleic acids)	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹ EVs coated with AuNP ²
1330	Phospholipid	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1334	Ring breathing of adenine	PANC1(Pancreatic cancer cell)	EVs with nanostars ⁸
1336	backbone deformation C α – H/C α – C stretching/CH ₂ ,CH ₃ twisting or wagging in proteins	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1354	Guanine (nucleic acid)	B16F10(melanoma cell)	EVs coated with AuNP ²
1360,1367, 1369.6	CH ₃ /CH ₂ twisting or bending mode of lipid/collagen	SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC HCC827(lung cancer cell)	biosilica/AgNP composite substrates ⁷ EVs coated with AuNP ² Au nanopyramid hybrid substrate ¹⁰
1370,1378	Carbohydrate	B16F10(melanoma cell), RBC HCC827(lung cancer cell)	EVs coated with AuNP ² Ag NCs on Au NR array substrate ⁴
1375,1376	Amide III	Lung cancer cell, HPAEpiC(normal cells)	GNP substrates ⁵
1378	Lipid	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1381	δ CH ₃ symmetric (lipids)	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹ EVs coated with AuNP ²

1381	C=O symmetric stretching, CH ₂ deformation, N – H in plane deformation (e.g. protein)	PANC1(Pancreatic cancer cell)	EVs with nanostars ⁸
1386-1390	symmetrical CH ₃ deformation in DNA/RNA, proteins, or lipids	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1388	DNA peak due to NH in-plane deformation	SK-BR3(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1394,1404	CH rocking	SKOV-3(ovarian cancer cell) NL-20, BEAS-20, L929(lung normal cells)	3D plasmonic nanobowl platform ⁶ Ag NCs on Au NR array substrate ⁴
1400	protein vibrational modes, e.g., CH ₂ deformations	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1416,1422	DNA bases	HPAEpiC(normal cell) H1975(lung cancer cell)	GNP substrates ⁵ Au nanopyramid hybrid substrate ¹⁰
1440	Lipid	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1443,1445,1460, 1448,1449	CH ₂ , CH ₃ deformation (e.g. protein backbone, acyl chain in lipids)	B16F10(melanoma cell), RBC SKOV-3(ovarian cancer cell) HCC827(lung cancer cell) PANC1(Pancreatic cancer cell)	EVs coated with AuNP ² biosilica/AgNP composite substrates ⁷ Ag NCs on Au NR array substrate ⁴ EVs with nanostars ⁸
1465,1466	lipids	B16F10(melanoma cell), RBC SKOV-3(ovarian cancer cell)	EVs with Au@AgNPs ¹ EVs coated with AuNP ² 3D plasmonic nanobowl platform ⁶
1466,1470,1480	overlapping of the CH deformation occurring in both lipids and proteins	Lung cancer cell CCD841-CoN, HPAEpiC(normal cells) HCT116(Colon cancer cell)	GNP substrates ⁵ Super-hydrophobic substrate ¹¹
1474.8,1481	Amide II (largely due to coupling of CN	H1975, HCC827(lung cancer cells)	Au nanopyramid hybrid substrate ¹⁰

	stretching & in-plane bending of N-H group		
1477	DMAP + δ (C-H) (e.g., lipid, protein)	B16F10(melanoma cell), RBC	EVs coated with AuNP ²
1490	DNA	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹
1500	conjugated ν -C=C- vibrations in nucleic acids	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1506.6	N=H bending, Cytosine	HCC827(lung cancer cell)	Au nanopyramid hybrid substrate ¹⁰
1510	DNA peak due to purine A, G ring	MDA-MB-231(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1528	ν (C-C) conjugated	B16F10(melanoma cell), RBC	EVs coated with AuNP ²
1539	Cytosine	H1299, H522(lung cancer cells)	GNP substrates ³
1542,1545	amide II (proteins)	B16F10(melanoma cell), RBC SKOV-3(ovarian cancer cell)	EVs with Au@AgNPs ¹ biosilica/AgNP composite substrates ⁷
1545	lipid band due to δ (CH ₃ ,CH ₂) in acyl chain	MDA-MB-231(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1552,1563,1588	Trp	SKOV-3(ovarian cancer cell) B16F10(melanoma cell), RBC Lung cancer cell HPAEpiC(normal cell)	3D plasmonic nanobowl platform ⁶ EVs with Au@AgNPs ¹ EVs coated with AuNP ² GNP substrates ⁵
1576	Guanine (nucleic acid)	B16F10(melanoma cell), RBC	EVs coated with AuNP ²
1584.8	Hydroxyproline	HCC827(lung cancer cell)	Au nanopyramid hybrid substrate ¹⁰
1590,1590.9	C-C ring vibration in aromatic groups	SKOV-3(ovarian cancer cell) H1975(lung cancer cell)	biosilica/AgNP composite substrates ⁷ Au nanopyramid hybrid substrate ¹⁰
1595	nucleic acid	H1975(lung cancer cell) SKOV-3(ovarian cancer cell)	Ag NCs on Au NR array substrate ⁴ biosilica/AgNP composite substrates ⁷

1600	Phe	SKOV-3(ovarian cancer cell)	3D plasmonic nanobowl platform ⁶
1605	lipid band due to the ergostero	MDA-MB-231(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1605.9,1608,1614,1618,1620	Cytosine (NH ₂), Ring C-C stretch of phenyl (1), Phenylalanine, tyrosine, vibration of C = C (protein)	H1975, HCC827(lung cancer cells) B16F10(melanoma cell), RBC SKOV-3(ovarian cancer cell)	Au nanopyramid hybrid substrate ¹⁰ EVs coated with AuNP ² Ag NCs on Au NR array substrate ⁴ EVs with Au@AgNPs ¹ biosilica/AgNP composite substrates ⁷
1622	Amide I, Tyr, Trp, Phe	Lung cancer cell HPAEpiC(normal cell)	GNP substrates ⁵
1630	tryptophan due to -C-N-O stretch	SK-BR3(breast cancer cell)	GO-GNS mixed-dimensional substrate ⁹
1630	amide I C=O stretching vibrations in proteins	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1630	Amide I (random coils of proteins)	normal cell(alveolar cell)	GNP substrates ³
1632	amide I α -helix and β structure (proteins)	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹
1650	amide I vibrations in proteins or C=C stretching in lipids	SKOV-3(ovarian cancer cell)	biosilica/AgNP composite substrates ⁷
1664	amide I (proteins)/DNA	B16F10(melanoma cell), RBC	EVs with Au@AgNPs ¹
1687	Amide I	Lung cancer cell	GNP substrates ⁵

Table S2. peak assignments of surface-enhanced Raman spectroscopy of plasma/serum-derived EVs

Peak(cm ⁻¹)	Origin	EVs source	Substrates
502,504	S-S disulfide bridge in cysteine	Lung cancer patients, healthy volunteers	GNP substrates ⁵
651	Tyr	Lung cancer patients, healthy volunteers	GNP substrates ⁵
734	Met, Adenine	Lung cancer patients, healthy volunteers	GNP substrates ⁵
787	Nucleic Acids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
830	C-O-O	healthy volunteers, pancreatic cancer patients	APS-mica ¹³
850-860	Polysaccharide Structure	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
864.1	Ribose vibration, one of the distinct RNA modes	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1003,1008, 1047	Phe	healthy volunteers Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients Lung cancer patients	Microstructured arrays containing AuNPs ¹² GNP substrates ⁵
1032	Phospholipid and/or Polysaccharide	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1051,1063.9, 1077,1124	C-C skeletal stretching	healthy volunteers, pancreatic cancer patients Lung cancer patients	APS-mica ¹³ Au nanopyramid hybrid substrate ¹⁰ GNP substrates ⁵
1128	Proteins and/or Ceramides	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance	Microstructured arrays containing AuNPs ¹²

(MGUS) patients			
1135	C-N	healthy volunteers	GNP substrates ⁵
1151	Lipids and nucleic acids (cytosine, guanine, adenine)	Lung cancer patients	GNP substrates ⁵
1157	β -Carotene Accumulation	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1170.4	C-H in-plane bending mode of tyrosine	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1173	Lipids and nucleic acids (cytosine, guanine, adenine)	healthy volunteers	GNP substrates ⁵
1209	Tryptophan and/or Phenylalanine	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1255.6	Lipids	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1302.9	Amide III (protein)	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1316,1316.1	Nucleic Acids and/or Collagen and/or Guanine	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients healthy volunteers	Microstructured arrays containing AuNPs ¹² Au nanopyramid hybrid substrate ¹⁰
1345.7	CH ₃ , CH ₂ wagging	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1373.3	T, A, G (ring breathing modes of the DNA/RNA bases)	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1376	Amide III	Lung cancer patients	GNP substrates ⁵
1378	Carbohydrate and/or Nucleic Acids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1386.2,1402	CH ₃ band	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰

			GNP substrates ⁵
1420	DNA bases	Lung cancer patients	GNP substrates ⁵
1427.2	Deoxyribose (B,Z- marker)	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1450	CH2 bending	healthy volunteers, pancreatic cancer patients	APS-mica ¹³
1457	Deoxyribose	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1459	C-H	Lung cancer patients, healthy volunteers	GNP substrates ⁵
1479.6	Amide II	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1515.8	Cytosine	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1539	Nucleic Acids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1589	Phenylalanine, hydroxyproline	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1655.2	Amide I of proteins	healthy volunteers	Au nanopyramid hybrid substrate ¹⁰
1672	Ceramide	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
869,872	Tyr	Lung cancer patients, healthy volunteers	GNP substrates ⁵
980,981	Trp, Val	Lung cancer patients, healthy volunteers	GNP substrates ⁵
1235-1285	Proteins and/or Nucleic Acids and/or Lipids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1296,1301	Amide III—collagen	Lung cancer patients, healthy volunteers	GNP substrates ⁵
1300-1400	CH2 twisting	healthy volunteers,	APS-mica ¹³

pancreatic cancer patients			
1335-1345	Nucleic Acids (Purine Bases) and/or Tryptophan and/or Glycine Backbone and/or Proline Side Chain	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1440-1450	Proteins and/or Lipids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1490-1500	Nucleic Acids	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1560-1580	Tryptophan and/or Nucleic Acids and/or Proteins and/or Carbohydrates	Multiple myeloma(MM)patients, monoclonal gammopathy of uncertain significance (MGUS) patients	Microstructured arrays containing AuNPs ¹²
1593,1596	Phe	Lung cancer patients, healthy volunteers	GNP substrates ⁵

Table3. Statistical classification method of the Raman spectra

Method	Samples	Sensitivity	Specificity	Ref.
PCA	Normal cell and lung cancer cell	95.3%, 91.67%	97.3%, 100%	³
	Breast cancer cell	100%	100%	¹⁴
	Ovarian cell and endometrial cancer cell	100%	99.2%	⁷
	6 volunteers and 14 breast cancer patients	91.67%	100%	¹⁴
PCA-LDA	Pancreatic cancer cell and prostate cancer cell and colorectal cancer cell	100%.	100%.	⁸
PC-DFA	Normal cell and lung cancer cell	90.6%	97.1%	¹³
PLS-DA	Normal cell and melanoma cell	92.0%, 95.1%	96.9%, 100%	²
	Red blood cell and melanoma cell	91.7%, 96.9%	96.9%, 91.7%	¹
	10 volunteers and 10 osteosarcoma patients	86%,	100%	¹⁵
Deep learning	10 volunteers and 43 Lung cancer patients	84%	85%	⁵

References

1. J. C. Fraire, S. Stremersch, D. Bouckaert, T. Monteyne, T. De Beer, P. Wuytens, R. De Rycke, A. G. Skirtach, K. Raemdonck, S. De Smedt and K. Braeckmans, *ACS Appl Mater Interfaces*, 2019, **11**, 39424-39435.
2. S. Stremersch, M. Marro, B. E. Pinchasik, P. Baatsen, A. Hendrix, S. C. De Smedt, P. Loza-Alvarez, A. G. Skirtach, K. Raemdonck and K. Braeckmans, *Small*, 2016, **12**, 3292-3301.
3. J. Park and M. Hwang, 2017.
4. K. Sivashanmugan, W.-L. Huang, C.-H. Lin, J.-D. Liao, C.-C. Lin, W.-C. Su and T.-C. Wen, *Journal of the Taiwan Institute of Chemical Engineers*, 2017, **80**, 149-155.
5. H. Shin, S. Oh, S. Hong, M. Kang, D. Kang, Y. G. Ji, B. H. Choi, K. W. Kang, H. Jeong, Y. Park, S. Hong, H. K. Kim and Y. Choi, *ACS Nano*, 2020, **14**, 5435-5444.
6. C. Lee, R. P. Carney, S. Hazari, Z. J. Smith, A. Knudson, C. S. Robertson, K. S. Lam and S. Wachsmann-Hogiu, *Nanoscale*, 2015, **7**, 9290-9297.
7. T. Rojalín, H. J. Koster, J. Liu, R. R. Mizenko, D. Tran, S. Wachsmann-Hogiu and R. P. Carney, *ACS Sens*, 2020, **5**, 2820-2833.
8. Y. Liu, W. Zhang, T. H. Phan, W. Chrzanowski, A. Rodger and Y. Wang, *Anal Methods*, 2020, **12**, 5908-5915.
9. A. Pramanik, J. Mayer, S. Patibandla, K. Gates, Y. Gao, D. Davis, R. Seshadri and P. C. Ray, *ACS Omega*, 2020, **5**, 16602-16611.
10. Z. Yan, S. Dutta, Z. Liu, X. Yu, N. Mesgarzadeh, F. Ji, G. Bitan and Y. H. Xie, *ACS Sens*, 2019, **4**, 488-497.
11. L. Tirinato, F. Gentile, D. Di Mascolo, M. L. Coluccio, G. Das, C. Liberale, S. A. Pullano, G. Perozziello, M. Francardi, A. Accardo, F. De Angelis, P. Candeloro and E. Di Fabrizio, *Microelectronic Engineering*, 2012, **97**, 337-340.
12. M. Russo, L. Tirinato, F. Scionti, M. L. Coluccio, G. Perozziello, C. Riillo, V. Mollace, S. Gratteri, N. Malara, M. T. Di Martino, G. Viglietto, P. Tagliaferri, P. Tassone, M. Rossi and P. Candeloro, *ACS Omega*, 2020, **5**, 30436-30443.
13. J. Carmicheal, C. Hayashi, X. Huang, L. Liu, Y. Lu, A. Krasnoslobodtsev, A. Lushnikov, P. G. Kshirsagar, A.

- Patel, M. Jain, Y. L. Lyubchenko, Y. Lu, S. K. Batra and S. Kaur, *Nanomedicine*, 2019, **16**, 88-96.
14. G. Li, N. Zhu, J. Zhou, K. Kang, X. Zhou, B. Ying, Q. Yi and Y. Wu, *J Mater Chem B*, 2021, **9**, 2709-2716.
15. Z. Han, J. Yi, Y. Yang, D. Li, C. Peng, S. Long, X. Peng, Y. Shen, B. Liu and L. Qiao, *Analyst*, 2021, **146**, 6496-6505.